Clair Health Secures $11 Million Seed Funding for Women's Hormone Wearable
Clair Health, a startup co-founded by 21-year-old Stanford graduate Jenny Duan, has raised $11 million in seed funding to develop a continuous, non-invasive hormone monitor for women. The investment round was led by Khosla Ventures, with additional support from a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. The company aims to introduce a wristband wearable that utilizes a combination of 10 biosensors and AI models to track and infer a woman's hormonal cycle.
Jenny Duan, a 21-year-old Stanford University graduate, has co-founded Clair Health and successfully closed an $11 million seed funding round. The funding, led by Khosla Ventures, will support the development of what the company describes as the first continuous, non-invasive hormone monitor designed specifically for women.
The Clair Health wearable wristband integrates ten biosensors, including biomagnetic sensors, to collect physiological signals such as skin temperature, heart rate variability, and electrodermal activity. These markers are then processed through AI models to determine a woman's phase in her hormonal cycle, offering an alternative to traditional blood or urine tests.
Duan noted that existing urine tests do not directly measure hormones but rather their metabolism by the body. Initial benchmarks showed Clair Health's AI accurately identified the menstrual cycle phase 94% of the time when compared against daily urine samples. Independent third-party studies, including one with Stanford, are currently underway to further validate the technology.
While other companies like WHOOP and Oura have expanded into women's health, Clair Health distinguishes itself by building its technology from the ground up to model the hypothalamic-pituitary-ovarian (HPO) axis, the hormonal feedback loop governing female physiology. The company holds provisional patents for its sensor configuration.
Clair Health plans to launch its product as a wellness device in November, with a goal of pursuing FDA clearance later. The company has already amassed a 25,000-person waitlist and sold out its presale. It has also received over 100 letters of intent from fertility clinics. Future plans include monitoring for perimenopause, calibration for hormone replacement therapy, and diagnostics for conditions like PCOS and endometriosis. The company is also implementing HIPAA compliance with zero-knowledge encryption and on-device computing to protect user health data.
The global femtech market is projected to nearly triple, from $39 billion in 2024 to $97 billion by 2030.
According to Fortune, Duan anticipates raising additional funding in approximately one year.
